Research compounds
Beta-endorphin
β-endorphin
Beta-endorphin is a 31-amino-acid endogenous opioid peptide produced in the pituitary and hypothalamus from proopiomelanocortin, the same precursor as ACTH and alpha-MSH. It is the molecule behind the popular idea of the "runner's high".
Also known as: beta endorphin, b-endorphin
- Status
- Beta-endorphin is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Approximately 20 to 40 minutes in plasma.
- How it's taken
- Not used therapeutically; research administration only
- Mechanism
- Other
How Beta-endorphin works
Beta-endorphin is a high-affinity mu opioid receptor agonist. Pituitary release into the circulation occurs with stress and exercise, while hypothalamic release acts centrally on pain modulation and reward. Because it is cleaved from proopiomelanocortin alongside ACTH, stress-induced release of the two is coupled.
What research has looked at
- It is the endogenous mu opioid agonist underlying stress-induced analgesia, a well-characterised physiological phenomenon.
- Its shared precursor with ACTH and alpha-MSH explains why stress, pigmentation and analgesia pathways are biochemically linked.
- Central beta-endorphin release contributes to exercise-associated mood effects, though endocannabinoids are now considered at least as important.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Circulating beta-endorphin does not cross the blood-brain barrier in meaningful amounts, so peripheral measurements do not reflect central activity — a point routinely misrepresented in popular accounts of the runner's high. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- As a mu opioid agonist, exogenous administration would carry the full opioid risk profile including respiratory depression, tolerance and dependence.
- It is degraded rapidly by peptidases and has no practical route of administration.
- Supplements claiming to raise beta-endorphin have no controlled evidence of doing so.
Sources
- PubMed research on beta-endorphin runner's high blood brain barrier · NIH · National Library of Medicine
- DrugBank record for beta-endorphin · DrugBank
- Active clinical trials for beta-endorphin · U.S. National Library of Medicine
Track Beta-endorphin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Beta-endorphin FAQ
What is Beta-endorphin?
Beta-endorphin is a 31-amino-acid endogenous opioid peptide produced in the pituitary and hypothalamus from proopiomelanocortin, the same precursor as ACTH and alpha-MSH. It is the molecule behind the popular idea of the "runner's high".
How does Beta-endorphin work?
Beta-endorphin is a high-affinity mu opioid receptor agonist. Pituitary release into the circulation occurs with stress and exercise, while hypothalamic release acts centrally on pain modulation and reward. Because it is cleaved from proopiomelanocortin alongside ACTH, stress-induced release of the two is coupled.
Is Beta-endorphin FDA approved?
No. Beta-endorphin is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Beta-endorphin?
Reported half-life: Approximately 20 to 40 minutes in plasma.
How is Beta-endorphin taken?
Not used therapeutically; research administration only.
What side effects have been reported with Beta-endorphin?
Reported in the sources: Circulating beta-endorphin does not cross the blood-brain barrier in meaningful amounts, so peripheral measurements do not reflect central activity — a point routinely misrepresented in popular accounts of the runner's high. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; As a mu opioid agonist, exogenous administration would carry the full opioid risk profile including respiratory depression, tolerance and dependence; It is degraded rapidly by peptidases and has no practical route of administration; Supplements claiming to raise beta-endorphin have no controlled evidence of doing so.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.